Unifuzol

Unifuzol (arginine sodium succinate) is an intravenous solution developed by POLYSAN Scientific & Technological Pharmaceutical Company for the treatment of peripheral vascular disease. The drug combines L-arginine, a precursor for nitric oxide synthesis that promotes vasodilation and improves endothelial function, with sodium succinate, which supports cellular metabolism and provides antihypoxic effects. Clinical evaluation has focused on its safety, tolerability, and pharmacokinetic profile, specifically assessing its impact on blood viscosity and vascular protection. It is typically administered as a 1.4% solution for infusion.

Brand names

UnifuzolUnifusol

Other names

arginine sodium succinate